463.43
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ALNY Giù?
Forum
Previsione
Precedente Chiudi:
$464.00
Aprire:
$468.68
Volume 24 ore:
771.27K
Relative Volume:
0.66
Capitalizzazione di mercato:
$60.75B
Reddito:
$2.46B
Utile/perdita netta:
$-319.09M
Rapporto P/E:
-187.86
EPS:
-2.4669
Flusso di cassa netto:
$-52.09M
1 W Prestazione:
-3.79%
1M Prestazione:
+1.10%
6M Prestazione:
+91.02%
1 anno Prestazione:
+57.80%
Alnylam Pharmaceuticals Inc Stock (ALNY) Company Profile
Nome
Alnylam Pharmaceuticals Inc
Settore
Industria
Telefono
(617) 551-8200
Indirizzo
675 WEST KENDALL STREET, CAMBRIDGE, MA
Confronta ALNY con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals Inc
|
463.43 | 60.82B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
VRTX
Vertex Pharmaceuticals Inc
|
421.39 | 108.36B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
577.95 | 61.02B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
817.32 | 50.01B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
310.81 | 34.05B | 4.56B | -176.77M | 225.30M | -1.7177 |
Alnylam Pharmaceuticals Inc Stock (ALNY) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-08-04 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2025-08-04 | Aggiornamento | Wolfe Research | Underperform → Peer Perform |
| 2025-07-30 | Ripresa | Raymond James | Outperform |
| 2025-07-21 | Iniziato | Truist | Buy |
| 2025-03-31 | Iniziato | Redburn Atlantic | Buy |
| 2025-03-24 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2024-11-12 | Downgrade | Wolfe Research | Peer Perform → Underperform |
| 2024-10-16 | Iniziato | Scotiabank | Sector Outperform |
| 2024-08-16 | Aggiornamento | Goldman | Neutral → Buy |
| 2024-02-16 | Downgrade | Goldman | Buy → Neutral |
| 2024-02-15 | Iniziato | Wolfe Research | Peer Perform |
| 2023-12-08 | Iniziato | Wells Fargo | Equal Weight |
| 2023-10-11 | Downgrade | Oppenheimer | Outperform → Perform |
| 2023-09-29 | Iniziato | Raymond James | Outperform |
| 2023-05-05 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2023-04-26 | Iniziato | SMBC Nikko | Neutral |
| 2023-03-21 | Iniziato | Bernstein | Outperform |
| 2023-01-18 | Iniziato | Canaccord Genuity | Buy |
| 2022-09-09 | Ripresa | Morgan Stanley | Equal-Weight |
| 2022-07-13 | Iniziato | Cantor Fitzgerald | Neutral |
| 2022-06-27 | Downgrade | Guggenheim | Buy → Neutral |
| 2022-06-07 | Iniziato | William Blair | Outperform |
| 2022-04-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2022-03-01 | Iniziato | Citigroup | Buy |
| 2022-02-03 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2022-01-03 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2021-11-22 | Aggiornamento | Goldman | Neutral → Buy |
| 2021-11-22 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2021-11-01 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2021-10-04 | Aggiornamento | UBS | Neutral → Buy |
| 2021-08-04 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2021-02-22 | Downgrade | Guggenheim | Buy → Neutral |
| 2021-02-12 | Downgrade | Citigroup | Buy → Neutral |
| 2021-02-12 | Reiterato | H.C. Wainwright | Buy |
| 2021-01-25 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2020-09-30 | Ripresa | Berenberg | Hold |
| 2020-09-08 | Iniziato | Citigroup | Buy |
| 2020-08-11 | Downgrade | Oppenheimer | Outperform → Perform |
| 2020-05-13 | Iniziato | RBC Capital Mkts | Sector Perform |
| 2020-05-07 | Downgrade | JP Morgan | Overweight → Neutral |
| 2020-04-24 | Ripresa | Evercore ISI | Outperform |
| 2020-03-19 | Iniziato | Berenberg | Buy |
| 2019-12-19 | Reiterato | Chardan Capital Markets | Buy |
| 2019-11-20 | Iniziato | Oppenheimer | Outperform |
| 2019-11-13 | Iniziato | BofA/Merrill | Buy |
| 2019-05-23 | Ripresa | Goldman | Neutral |
| 2019-04-12 | Iniziato | Evercore ISI | Outperform |
| 2019-03-06 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2019-03-05 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2019-01-23 | Iniziato | UBS | Neutral |
| 2018-10-01 | Iniziato | Cantor Fitzgerald | Overweight |
| 2018-08-13 | Reiterato | Stifel | Buy |
| 2018-08-07 | Aggiornamento | Stifel | Hold → Buy |
| 2018-05-04 | Reiterato | Stifel | Hold |
| 2018-03-28 | Iniziato | Evercore ISI | In-line |
Mostra tutto
Alnylam Pharmaceuticals Inc Borsa (ALNY) Ultime notizie
Why Alnylam Pharmaceuticals Inc. stock is recommended by analysts2025 Earnings Surprises & Risk Adjusted Buy/Sell Alerts - newser.com
Is Alnylam Pharmaceuticals Inc. (DUL) stock vulnerable to rate hikes2025 Price Momentum & Consistent Growth Stock Picks - newser.com
Has Alnylam Pharmaceuticals Inc. found a price floorInflation Watch & Technical Pattern Based Buy Signals - newser.com
What downside risks could hit Alnylam Pharmaceuticals Inc. (DUL) stockJuly 2025 Momentum & Accurate Trade Setup Notifications - newser.com
Is Alnylam Pharmaceuticals Inc. stock resilient to inflation2025 Sector Review & Safe Entry Zone Tips - newser.com
Is Alnylam Pharmaceuticals Inc. (DUL) stock overpriced at current multiplesWeekly Profit Report & Long-Term Capital Growth Ideas - newser.com
Is it time to cut losses on Alnylam Pharmaceuticals Inc.Trade Exit Report & Advanced Swing Trade Entry Plans - newser.com
Using data filters to optimize entry into Alnylam Pharmaceuticals Inc.2025 Risk Factors & AI Powered Market Entry Strategies - newser.com
How to recover losses in Alnylam Pharmaceuticals Inc. stockWall Street Watch & Long-Term Capital Growth Ideas - newser.com
Alnylam Pharmaceuticals (ALNY) Earnings Expected to Grow: What to Know Ahead of Next Week's Release - Yahoo Finance
Custom watchlist performance reports with Alnylam Pharmaceuticals Inc.2025 Market Outlook & Daily Stock Momentum Reports - newser.com
Published on: 2025-10-21 18:00:20 - newser.com
Published on: 2025-10-21 15:17:29 - newser.com
Are Alnylam Shares Still Attractive After a 110% Surge and Fresh Pipeline News? - simplywall.st
Alnylam Pharmaceuticals, Inc. (ALNY) stock price, news, quote and history - Yahoo
Will Alnylam Pharmaceuticals Inc. (DUL) stock sustain bullish trend into 2025Trend Reversal & Risk Adjusted Buy/Sell Alerts - newser.com
Is Alnylam Pharmaceuticals Inc. reversing from oversold territoryMarket Risk Report & Long-Term Growth Stock Strategies - newser.com
Alnylam Pharmaceuticals Inc Azioni (ALNY) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Alnylam Pharmaceuticals Inc Azioni (ALNY) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Greenstreet Yvonne | Chief Executive Officer |
Oct 02 '25 |
Sale |
452.05 |
8,924 |
4,034,085 |
65,409 |
| Tanguler Tolga | EVP, Chief Commercial Officer |
Oct 02 '25 |
Sale |
452.05 |
1,405 |
635,126 |
27,438 |
| Fitzgerald Kevin Joseph | CSO & EVP, Head of Research |
Oct 02 '25 |
Sale |
452.05 |
2,441 |
1,103,451 |
25,231 |
| Garg Pushkal | EVP Chief R&D |
Oct 03 '25 |
Sale |
451.48 |
3,022 |
1,364,387 |
20,221 |
| Garg Pushkal | EVP Chief R&D |
Oct 02 '25 |
Sale |
452.05 |
2,937 |
1,327,675 |
23,243 |
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):